Most-favored-nation drug pricing agreements now in effect

Trump Extends Most-Favored-Nation Drug Pricing Deals to Medicaid in All 50 States, Saving $64 Billion

Imagine walking into a pharmacy and being told you’ll pay three times what a customer in Paris or Tokyo pays for the exact same pill. No special formula, no premium version – just a bigger bill because you happen to live in the United States.

That’s been the reality for American families for decades. The U.S. has long paid nearly three times what other developed nations spend on prescription drugs – a fact that every politician in Washington has lamented and virtually none have fixed. Administrations came and went. Promises piled up like unpaid invoices. The pharmaceutical lobby wrote checks, and Congress looked the other way.

Sound familiar? It should. We’ve been hearing this song our entire lives. But last Friday, something concrete actually happened – and I mean concrete with a dollar sign$ attached.

President Trump announced from the Oval Office that his most-favored-nation drug pricing agreements with pharmaceutical companies are officially being extended to Medicaid programs in all 50 states, Washington, D.C., and Puerto Rico. Through the GENEROUS Medicaid Payment Model, states will receive rebates ensuring they never pay more than the MFN price on expensive brand-name drugs.

Twenty-six major pharmaceutical companies – from Eli Lilly and Novo Nordisk to AstraZeneca and AbbVie – have signed on voluntarily.

Read about it...